Yamamoto, Noboru
Satouchi, Miyako
Doi, Toshihiko
Fujiwara, Yutaka
Yanagitani, Noriko
Kawa, Yoshitaka
Yoh, Kiyotaka
Leopold, Lance
Munteanu, Mihaela
Sawada, Takashi
Han, Shirong
Noguchi, Kazuo
Nishio, Makoto
Funding for this research was provided by:
Funding for this research was provided by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and Incyte Corporation, Wilmington, DE, USA.
Article History
Received: 6 December 2023
Accepted: 15 January 2024
First Online: 26 March 2024
Declarations
:
: Noboru Yamamoto: None.Miyako Satouchi: Honoraria (lecture fees) from Chugai, AstraZeneca, Eli Lilly, Taiho, MSD, Pfizer, Novartis, Bristol-Myers Squibb, Ono, Takeda, Daiichi-Sankyo, Amgen, and Merck Biopharma; and has received clinical trial funding from Chugai, AstraZeneca, MSD, Janssen, Amgen, Taiho, Bristol-Myers Squibb, Pfizer, Daiichi-Sankyo, and Eisai.Toshihiko Doi: Grants or contracts to institution from PRA Health Sciences, MSD, Daiichi Sankyo, Amgen, Taiho, GSK, ONO Pharma, Janssen Pharma, Boehringer Ingelheim, Pfizer, BMS, Abbvie, Eisai, RIN Institute, Chugai Pharma, Shionogi; Consulting fees from Sumitomo Pharma, Oncolys BioPharma, Takeda, Chugai Pharma, Boehringer Ingelheim, Nano Carrier, Rakuten Medical, Otsuka Pharma, KAKEN Pharma, Kyowa Kirin, Shionogi, PRA Health Science, A2 Health Care, Noil-Immune Biotech; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or education events from Daiichi Sankyo; participation on data safety monitoring board or advisory board for Gilead, Pfizer, Amgen, and Zymeworks Biopharma.Yutaka Fujiwara: Honoraria for lectures from AstraZeneca, Amgen, Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Merck Biopharma, MSD, Novartis, Ono Pharmaceutical, Pfizer, Takeda, Taiho, and Yakult; participation on advisory board for AstraZeneca, Chiome Bioscience, Daiichi Sankyo, Micron, Otsuka Pharmaceutical, and Ono Pharmaceutical.Noriko Yanagitani: Payment or honoraria for lectures from Ono Pharmaceuticals, Chugai Pharmaceutical, Taiho Pharmaceutical, Bristol Myers Squibb, Lilly, AstraZeneca, Takeda, and Pfizer.Yoshitaka Kawa: None.Kiyotaka Yoh: Grants or contracts from any entity to institution from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Chugai, Daiichi Sankyo, Lilly, MSD, Pfizer, Taiho, Takeda; Consulting fees to self from Boehringer Ingelheim; honoraria for lectures from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Janssen, Kyowa Kirin, Lilly, Merck Serono, Novartis, Ono, Otsuka, Taiho, and Takeda.Lance Leopold: Employee and stockholder of Incyte Corporation.Mihaela Munteanu: Employee and stockholder of Incyte Corporation.Takashi Sawada: Employee of MSD K.K., Tokyo, Japan.Shirong Han: Employee of MSD K.K., Tokyo, Japan.Kazuo Noguchi: Employee of MSD K.K., Tokyo, Japan.Makoto Nishio: Grants and personal fees from Ono Pharmaceutical, Bristol Myers Squibb, Pfizer, Chugai Pharmaceuticals, Eli Lilly, Taiho Pharmaceutical, AstraZeneca, MSD, Novartis, Daiichi Sankyo, and Takeda Pharmaceutical Company Limited; and has received personal fees from Boehringer-Ingelheim, Merck Biopharma, Teijin Pharma Limited, and AbbVie.
: This study was performed in line with the principles set forth in the Declaration of Helsinki. Approval was granted by the appropriate institutional review boards at each study site.
: Written informed consent was obtained from all individual participants included in the study.
: All authors approved the final version of the manuscript and the decision to submit it for publication.